Investors that are looking for some new shares to buy might want to look at the two listed below.
These two ASX 200 shares have been tipped to climb meaningfully higher from where they trade today. Here's what you need to know about them:
CSL Limited (ASX: CSL)
The first ASX 200 share that analysts are saying investors should buy is biotherapeutics giant, CSL.
Over the last century, the company has developed a range of lifesaving and lucrative plasma therapies and vaccines. It continues this work today with its huge annual investment in R&D and is also in the process of acquiring Vifor Pharma, which is focused on iron deficiency, nephrology and cardio-renal therapies.
Citi is positive on CSL and sees plenty of upside ahead for its shares. Particularly given its belief that CSL will deliver above consensus earnings in the coming years. The broker has a buy rating and $335.00 price target. Citi said:
We expect the market to shift its focus to the strong underlying plasma product demand, and the closure the Vifor deal, both of which should lead to strength in the share price.
Our FY23-24 EPS estimates remain 5-6% above consensus (we have included the Vifor consensus estimates in our forecasts). The next catalyst will be the closure of the Vifor transaction which is now expected to complete by the end of Sept (previously June). Maintain Buy, A$335 TP.
Goodman Group (ASX: GMG)
Another ASX 200 share that is highly rated is Goodman. It is a global integrated commercial and industrial property company with a world class property portfolio.
Goodman's high quality properties have exposure to key growth markets such as ecommerce and are in demand with tenants. The company also has a development pipeline which looks set to support further solid earnings growth in the coming years.
Citi is also positive on Goodman's future. Its analysts currently have a buy rating and $29.50 price target on its shares. The broker expects Goodman to outperform its upgraded earnings guidance in FY 2022.
Its analysts commented:
Similar to previous periods, we see FY22 guidance as conservative given strong FUM growth into 4Q22, off the back of development completions and rising asset values (as GMG's book cap rates are softer than market).
Moreover, despite fears, we see the growth outlook as being robust for FY23 as well given solid demand for industrial (which is driving market rental growth above longer-term averages) and ongoing investment demand, which should support asset value and AUM growth. We re-iterate Buy.
